Molbio Unicorn Investor

Battery-operated Truenat platform works in resource-limited settings, delivering decentralized diagnosis within an hour.

Same Truenat platform diagnoses TB, COVID, Hepatitis B/C, HIV, and HPV.

Truenat tests supplied at reduced pricing across all countries supported by the Global Fund, USAID and Stop TB Partnership.

Under the 2023 Global Fund/USAID/Stop TB Partnership deal, Molbio committed to a global-standard service level agreement covering instrument service and maintenance, backed by defined key performance indicators.

Truenat devices are installed in more than 8,000 Community/Primary Health Centres across India under the government's National Tuberculosis Elimination Programme (NTEP) — a long-running, large-scale institutional relationship with the Government of India.

Truenat devices connect over cloud, GPRS and Wi-Fi, letting Molbio monitor installed instruments from a central hub and help client labs streamline operations — an ongoing, semi-automated support layer on top of the hardware sale.

Molbio runs five manufacturing facilities in India (two in Goa, one in Visakhapatnam, two in Bengaluru) with annual capacity of roughly 3,600 diagnostic devices and 3.9 crore Truenat test kits.

Product design and development for the Truenat platform is carried out through Bigtec Labs, Molbio's R&D subsidiary, which designs point-of-care diagnostic platforms for resource-limited settings.

IPO proceeds are earmarked primarily for expanding R&D capabilities — including building a new R&D facility and a 'Center of Excellence' — plus upgrading manufacturing capacity across existing plants.

Joint 2023 collaboration reducing Truenat TB test pricing and guaranteeing service levels across countries they support.

Truenat MTB and MTB Plus rapid TB tests priced at under US$8 per test under the 2023 Global Fund/USAID/Stop TB Partnership deal.

Raw material consumption was Molbio's single largest FY25 expense line at roughly ₹413 crore, making up more than half of its total cost base.

Employee benefits expense rose 61% year-on-year to roughly ₹103 crore in FY25 as Molbio scaled headcount alongside revenue growth.

Advertising and marketing expenses nearly doubled to roughly ₹22 crore in FY25.

Molbio invested about ₹68.6 crore (₹685.7 million) in research and development in FY25, roughly 7% of that year's revenue.